• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国国家卫生与临床优化研究所(NICE)评估功能的影响。

Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).

作者信息

Buxton M

机构信息

Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UK UB8 3PH.

出版信息

Value Health. 2001 May-Jun;4(3):212-6. doi: 10.1046/j.1524-4733.2001.43079.x.

DOI:10.1046/j.1524-4733.2001.43079.x
PMID:11705183
Abstract

The National Institute of Clinical Excellence (NICE) has three main roles. It provides guidance to the National Health Service (NHS) on the use of selected new and existing technologies (the appraisal process), provides clinical guidelines for clinicians and physicians in important treatment areas, and develops audit methodologies. This paper discusses the NICE appraisal process. The specific steps of the appraisal process are described, including the basis for topic selection. An overview of NICE guidelines for manufacturers and sponsors is reported. First-year experience is assessed, reflecting on the quality of submitted evidence, and the content of the forthcoming program is presented. Finally, the impact of NICE appraisals is explored in terms of potential benefits and risks.

摘要

英国国家临床优化研究所(NICE)有三个主要职责。它就选定的新技术和现有技术的使用向国民保健制度(NHS)提供指导(评估过程),为重要治疗领域的临床医生和内科医生提供临床指南,并制定审核方法。本文讨论了NICE的评估过程。描述了评估过程的具体步骤,包括主题选择的依据。报告了NICE给制造商和赞助商的指南概述。评估了第一年的经验,反思了提交证据的质量,并介绍了即将开展的项目的内容。最后,从潜在的益处和风险方面探讨了NICE评估的影响。

相似文献

1
Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).英国国家卫生与临床优化研究所(NICE)评估功能的影响。
Value Health. 2001 May-Jun;4(3):212-6. doi: 10.1046/j.1524-4733.2001.43079.x.
2
Pharmaceutical regulation: the early experience of the NHS National Institute for Clinical Excellence (NICE) appraisal process--where are we headed?
Value Health. 2001 Jan-Feb;4(1):8-11. doi: 10.1046/j.1524-4733.2001.004001008.x.
3
The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.英国国家卫生与临床优化研究所的癌症技术评估项目。
Lancet Oncol. 2003 Apr;4(4):242-50. doi: 10.1016/s1470-2045(03)01036-2.
4
National Institute for Clinical Excellence (NICE): Is economic appraisal working?国家卫生与临床优化研究所(NICE):经济评估是否有效?
Pharmacoeconomics. 2002;20 Suppl 3:95-105. doi: 10.2165/00019053-200220003-00010.
5
National Institute for Clinical Excellence (NICE). HTA rhyme and reason?国家临床优化研究所(NICE)。卫生技术评估有何道理?
Int J Technol Assess Health Care. 2002 Spring;18(2):166-70. doi: 10.1017/s026646230200017x.
6
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.为 NICE 何时应仅在适当设计的证据开发计划背景下推荐使用卫生技术制定决策框架提供信息。
Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460.
7
Quality, innovation, and value for money: NICE and the British National Health Service.质量、创新与性价比:英国国家卫生与临床优化研究所(NICE)与英国国家医疗服务体系(NHS)
JAMA. 2005 Nov 23;294(20):2618-22. doi: 10.1001/jama.294.20.2618.
8
On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.英国的“国民健康与临床优化研究所”(NICE):英格兰和威尔士国民医疗服务体系(NHS)技术评估指南
Health Econ. 2002 Apr;11(3):185-91. doi: 10.1002/hec.706.
9
Evidence-informed evidence-making.基于证据的证据生成
J Health Serv Res Policy. 2008 Jul;13(3):167-73. doi: 10.1258/jhsrp.2008.008027.
10
ABPI call for NICE guidance to be made mandatory.英国血压协会呼吁将英国国家卫生与临床优化研究所的指南强制推行。
Lancet Oncol. 2003 Apr;4(4):203-4. doi: 10.1016/s1470-2045(03)01029-5.

引用本文的文献

1
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria.审查英国国家卫生与临床优化研究所单一技术评估的一致性:阵发性夜间血红蛋白尿评估综述
Pharmacoeconomics. 2025 May;43(5):499-508. doi: 10.1007/s40273-025-01472-5. Epub 2025 Feb 12.
2
The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.英国国家卫生与临床优化研究所的政治社会学:探究英国的药品成本效益监管
Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878.
3
Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review.
非小细胞肺癌诊断与治疗建议的一致性:一项系统综述
Transl Lung Cancer Res. 2021 Jun;10(6):2715-2732. doi: 10.21037/tlcr-21-423.
4
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.利用健康技术评估来评估新药的价值:在八个欧洲国家进行的系统评价和专家咨询的结果。
Eur J Health Econ. 2018 Jan;19(1):123-152. doi: 10.1007/s10198-017-0871-0. Epub 2017 Mar 16.
5
Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.药品的优先级设定。报销和临床指南委员会对卫生经济证据的使用。
Eur J Health Econ. 2004 Feb;5(1):28-35. doi: 10.1007/s10198-003-0195-0.